SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring for people with diabetes, announced today the U.S. Centers for Medicare & Medicaid Services (CMS) is ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM) the leader in continuous glucose monitoring (CGM) for people with diabetes, is pleased to announce the Food and Drug Administration (FDA) ...

Randomised controlled trial (RCT) assessed impact of two glucose monitoring systems on hypoglycaemia in people with type 1 diabetes EDINBURGH, Scotland, Jan. 30, 2018 /PRNewswire/ -- DexCom, Inc.

The FDA has approved San Diego, California-based Dexcom for a Bluetooth-enabled continuous glucose monitor (CGM), called the G5 Mobile CGM system. Correction: A previous version of this article ...

San Diego, CA-based DexCom, Inc.DXCM, a renowned medical device company, announced the U.S. FDA approval for its G5 Mobile CGM (continuous glucose monitoring) system. Notably, G5 Mobile is the only ...

The markets seem to be happy with South San Francisco, CA-based DexCom, Inc.DXCM. The company's stock price rallied 4.8% to close at $82.62 yesterday following its announcement, that the Centers for ...

In the United States, diabetes patients who use the Dexcom G5 Mobile continuous glucose monitoring system have had the convenience of viewing their blood glucose data on their smartphones. Users of ...

A new diabetes device may make tracking blood sugars and taking medication easier. The U.S. Food and Drug Administration said Tuesday that the Dexcom G5 continuous glucose monitoring system (CGM) can ...

The Food and Drug Administration (FDA) has expanded the use of Dexcom's G5 Mobile Continuous Glucose Monitoring (CGM) System to allow for replacement of blood glucose testing for diabetes treatment ...

FDA classifies this as a Class I recall, which means using the device could result in adverse health effects or death. Dexcom Inc., has recalled its G4 Platinum and G5 Mobile continuous glucose ...

As expected, an FDA panel voted in favor of giving Dexcom’s ($DXCM) G5 continuous glucose monitor a nonadjunctive indication that would allow it to be used in place ...

For the first time, the US Food and Drug Administration has approved the use of a continuous glucose monitoring (CGM) system to replace finger-stick testing for determining insulin doses. The decision ...